CLR’s MPC™ and Phytosan™ NewAge: New Clinical Data Push Longevity-Focused Actives Toward Mainstream Skincare

Table of Contents

1. Key Highlights:
2. Introduction
3. Why longevity-focused skincare matters now
4. MPC™ – Milk Peptide Complex: rebuilding the skin scaffold and the dermal–epidermal junction
5. Phytosan™ NewAge: stabilizing cells by addressing genomic instability
6. How complementary mechanisms create durable outcomes
7. Clinical evidence: interpreting the in vivo results
8. Formulation strategies and product concepts
9. Safety, regulatory and claims considerations
10. Market implications and commercial positioning
11. Real-world precedents and comparable actives
12. Practical questions formulators and brands should ask suppliers
13. How consumers should evaluate “longevity” products
14. Case study scenarios: integrating MPC™ and Phytosan™ NewAge into product lines
15. Limitations and areas for further research
16. Where this fits into the broader science-based skincare movement
17. Contact and sourcing considerations
18. Closing perspective
19. FAQ

Key Highlights:

• CLR has relaunched two actives—MPC™ (Milk Peptide Complex) and Phytosan™ NewAge—with updated in vivo data showing rapid improvements in skin firmness and wrinkle reduction: MPC™ shows visible results in 14 days; Phytosan™ NewAge demonstrates significant wrinkle reduction and enhanced firmness and elasticity after 42 days.
• The two ingredients address complementary drivers of ageing: MPC™ rebuilds skin structure at the dermal and dermal–epidermal junction, while Phytosan™ NewAge supports epidermal stem cell vitality and DNA repair to reduce genomic instability—together offering a strategy for durable, longevity-driven skin benefits.

Introduction

Skincare development is shifting away from single-ingredient promises and toward integrated strategies that change how skin ages over time. CLR Chemisches Laboratorium Dr. Kurt Richter GmbH has repositioned two established actives—MPC™ (Milk Peptide Complex) and Phytosan™ NewAge—and backed them with new human data to meet that demand. The updated studies show early structural improvements with MPC™ and longer-term cellular benefits with Phytosan™ NewAge. These outcomes suggest a pairing that targets both the tissue architecture that determines visible signs and the cellular processes that define resilience. The following analysis dissects the science behind each ingredient, examines the clinical evidence, explores formulation and regulatory considerations, and outlines how these actives fit into broader longevity-focused product strategies.

Why longevity-focused skincare matters now

Consumers expect more than transient smoothing or temporary tightening. They want interventions that slow, stabilize, or reverse the biological processes that produce signs of ageing. Longevity-focused skincare reframes product development around sustained outcomes: preserving barrier function, maintaining the dermal scaffold, and protecting the genomic and stem-cell mechanisms that enable healthy renewal.

Scientific frameworks for ageing—such as the hallmarks of ageing—identify genomic instability, stem cell exhaustion, and loss of extracellular matrix integrity as core contributors. Skincare that addresses these mechanisms does not promise instantaneous perfection. Instead, it seeks measurable shifts in the trajectory of skin ageing: fewer new wrinkles, a stronger barrier, and preserved elasticity. That approach places a premium on clinical substantiation that captures both short-term aesthetic improvements and indicators of long-term resilience.

CLR’s renewed focus on MPC™ and Phytosan™ NewAge reflects that strategic pivot. One active targets the structural scaffold; the other targets cellular stability. Together, they form a complementary toolkit for formulators aiming to back claims with mechanistic rationale and human data.

MPC™ – Milk Peptide Complex: rebuilding the skin scaffold and the dermal–epidermal junction

Peptides have been a mainstay of anti-ageing formulations for years. Many operate as signaling molecules that induce fibroblasts and other resident cells to increase synthesis of structural proteins. MPC™ is a milk-derived peptide complex designed to act at two critical locations: the dermis and the dermal–epidermal junction (DEJ). The DEJ is a specialized interface where the epidermis connects to the dermal matrix; its integrity is essential for mechanical support, nutrient exchange, and the appearance of smooth, firm skin.

Why the DEJ matters With advancing age, the DEJ flattens and key anchoring proteins decline. That undermines the skin’s mechanical cohesion and contributes to sagging, laxity, and a softer appearance of lines. Restoring DEJ components—collagens IV and VII, laminins and other anchoring proteins—improves resistance to shearing and helps maintain a taut, youthful contour. A peptide complex that stimulates production of those proteins can therefore have outsized effects on perceived firmness.

What MPC™ does CLR reports that MPC™ stimulates the production of structural proteins and supports optimal skin regeneration. In vivo data show visible improvements in firmness and a reduction in wrinkles within 14 days, with outcomes significantly better than placebo. The rapidity of the response suggests mechanisms that include increased synthesis of extracellular matrix components, improved DEJ architecture, and acceleration of turnover processes that renew the dermal scaffold.

How formulators commonly use peptide complexes Peptide complexes are frequently incorporated into serums and targeted treatments due to their potency at lower concentrations and their compatibility with a range of delivery systems. For MPC™, a logical approach is to deploy it in a lightweight, bioavailable vehicle designed for rapid skin penetration without compromising stability. Combining MPC™ with humectants and matrix-supportive ingredients amplifies visible effects while protecting the peptide’s activity.

Practical considerations

• Delivery to the dermal layer and DEJ requires either small peptide fragments or encapsulation strategies that improve penetration. Liposomal formulations, biodegradable nanoparticles, or microemulsions are commonly used.
• Peptides perform best in stable, buffered formulations. pH, preservative systems, and potential interactions with ascorbic acid or benzoyl peroxide must be evaluated during formulation.
• When immediate visible tightening is marketed, substantiate the claim with the specific in vivo data and clarify the measurement method and time frame.

Phytosan™ NewAge: stabilizing cells by addressing genomic instability

Genomic instability ranks among the primary hallmarks of ageing and refers to the cumulative DNA damage and mutation accumulation that compromise cellular function. In skin, genomic instability affects keratinocytes and epidermal stem cells, reducing regenerative capacity and increasing susceptibility to environmental stressors. Phytosan™ NewAge is formulated from organic, non-GMO soybeans and targets these cellular drivers.

Mechanisms relevant to skin longevity Two cellular processes are central here: DNA repair pathways and stem cell vitality. Efficient DNA repair—through systems such as nucleotide excision repair (NER) and base excision repair (BER)—removes lesions caused by ultraviolet radiation, oxidative stress, and other insults. Stem cells in the epidermis maintain tissue renewal; when their function declines, epidermal thinning, impaired barrier recovery, and slower wound repair follow.

What Phytosan™ NewAge does CLR states that Phytosan™ NewAge supports epidermal stem cell vitality, strengthens natural DNA repair mechanisms, and enhances long-term skin resilience. In vivo results indicate significant reduction of wrinkles after 42 days, alongside measurable improvements in firmness and elasticity. Those changes point to cumulative cellular benefits that require longer intervals to manifest—consistent with the biology of genomic stabilization and stem-cell mediated renewal.

Soy-derived actives in context Soy and soybean derivatives have a long history in cosmetics. Isoflavones such as genistein and daidzein exhibit antioxidant activity and modulate signalling pathways relevant to skin health. Phytosan™ NewAge appears to be an evolved fraction, formulated to preserve or concentrate molecular constituents that support DNA repair and stem cell function without relying solely on classical estrogenic or antioxidant pathways.

Formulation and application considerations

• Phytosan™ NewAge lends itself to nightly repair products, leave-on creams, and concentrated boosters aimed at long-term improvements.
• Stability and protection from oxidation are essential for plant-derived actives. Antioxidant-compatible packaging (airless pumps) and appropriate formulation buffers preserve efficacy.
• Positioning Phytosan™ NewAge in multi-step regimens emphasizes its role in long-term resilience rather than rapid visible smoothing.

How complementary mechanisms create durable outcomes

MPC™ and Phytosan™ NewAge approach ageing from different but complementary angles. MPC™ acts relatively quickly on the extracellular matrix and DEJ, creating structural gains that translate into visible firmness and wrinkle reduction in a matter of days to weeks. Phytosan™ NewAge works on the cellular machinery that governs renewal and repair, producing deeper changes in resilience and elasticity over several weeks.

When combined in a regimen, these mechanisms provide both immediate and sustained benefits. Structural reinforcement reduces the mechanical forces that exacerbate wrinkle formation. Cellular stabilization minimizes new damage and maintains a higher baseline of regenerative capacity. Together, they address both symptom and cause.

This dual approach mirrors successful medical models that pair symptomatic relief with disease-modifying therapy. In cosmetology, that means users can see early improvements while also investing in interventions that slow or alter the underlying ageing trajectory.

Clinical evidence: interpreting the in vivo results

CLR reports in vivo outcomes for both actives: MPC™ produced visible firmness and wrinkle reduction within 14 days and outperformed placebo; Phytosan™ NewAge reduced wrinkles significantly after 42 days and improved firmness and elasticity.

What “in vivo” implies In vivo indicates human testing. That carries more weight than in vitro or ex vivo assays because it captures complex interactions among formulation, skin barrier, microbiome, and user behavior. However, not all in vivo studies are the same. Key methodological attributes that determine credibility include sample size, control groups (placebo or vehicle), blinding, objective measurement methods (optical profilometry, cutometry, ultrasound), and statistical analysis.

Why time points matter Short-term endpoints (two weeks) often reflect mechanisms such as water-binding, mild topical tightening, or rapid induction of matrix protein synthesis. Mid-term endpoints (six weeks) capture processes like cumulative collagen remodeling, elastin stabilization, and improvements driven by restored cellular function. The 14-day result for MPC™ suggests early structural or biomechanical effects, whereas the 42-day Phytosan™ NewAge outcomes align with cellular repair timelines.

Recommended transparency in claims Manufacturers and marketers should disclose key study details: number of participants, demographics, study design (double-blind, randomized), endpoints, and measurement tools. That transparency builds trust with regulators, formulators, and consumers. It also helps buyers and R&D teams evaluate suitability for specific product concepts.

Formulation strategies and product concepts

Integrating these actives into commercial products requires thoughtful formulation to preserve activity and optimize delivery.

Product archetypes

• Daytime serum: Lightweight serum with MPC™ for visible firmness and an immediate lift; pairing with SPF protects gains.
• Night repair cream: Phytosan™ NewAge in a richer base to support overnight DNA repair and stem cell recovery.
• Dual-action booster: Concentrated drops containing both actives for targeted application to nasolabial folds, crow’s feet, or the neck.
• Layered regimen: AM use of MPC™ followed by antioxidant and SPF; PM application of Phytosan™ NewAge and a retinoid where tolerated.
• Professional treatments: High-concentration in-clinic ampoules for controlled delivery, followed by maintenance products for home use.

Delivery and stability

• Penetration enhancers and encapsulation help peptides and plant fractions reach target layers without compromising stability.
• Buffered systems and antioxidants in formulations prevent degradation of sensitive components.
• Packaging—airless dispensers or opaque containers—limits oxidation and photodegradation.

Combining with actives commonly used in anti-ageing

• Sunscreen: Daily photoprotection is non-negotiable; it preserves both structural and genomic benefits.
• Retinoids: A proven remodeler of collagen synthesis; pairing with Phytosan™ NewAge could be synergistic but requires tolerance testing for irritation.
• Hyaluronic acid and humectants: These amplify visible plumping and support peptide activity by optimizing hydration.
• Antioxidants: Complement DNA repair by reducing oxidative load.

Compatibility testing and claim stacking Formulators must test for chemical compatibility, pH stability, and sensory acceptance. When combining ingredients that address different ageing mechanisms, claims should reflect the distinct timelines and endpoints—for example, “Visible firmness in 14 days” alongside “Improved elasticity and wrinkle reduction in 42 days” where supported by study data.

Safety, regulatory and claims considerations

Cosmetic actives must pass safety standards and be marketed within regulatory frameworks that vary by jurisdiction.

Safety assessments

• Toxicological profiles: Suppliers typically provide safety dossiers including irritation, sensitization, and mutagenicity data.
• Human repeat insult patch tests and controlled usage trials inform irritation potential for leave-on products.
• For natural or organic claims, suppliers must substantiate sourcing and processing.

Regulatory positioning

• Cosmetic vs therapeutic claims: Avoid language that implies disease treatment. Focus claims on appearance, resilience, and structural improvement.
• INCI naming and labeling: Ensure correct INCI listing for ingredients and maintain transparency about proprietary names versus active fractions.
• Claim substantiation: Document clinical study protocols and results to defend marketing claims before regulatory bodies and third-party reviewers.

Sourcing and certifications

• Phytosan™ NewAge’s organic, non-GMO sourcing can be a market differentiator. Brands using it should request certificates of analysis and organic certification where relevant.
• For milk-derived actives, allergen risk and source traceability need to be managed. Clarify whether hydrolyzed milk peptides present allergen concerns and whether the ingredient is dairy-free in final formulations.

Market implications and commercial positioning

The relaunch of MPC™ and Phytosan™ NewAge aligns with several market trends: demand for evidence-backed actives, interest in longevity-oriented claims, and willingness among consumers to invest in multi-step regimens that promise durable outcomes.

Commercial narratives that resonate

• Evidence-first messaging: Highlight human data with specific endpoints and timeframes.
• Mechanistic clarity: Explain how the ingredients work—structural rebuilding versus genomic stabilization—without overstating.
• Regimen framing: Position products as part of a daily practice that includes photoprotection and targeted repair.

Pricing and positioning Actives with clinical backing often justify premium pricing, especially when paired with certified sourcing (organic, non-GMO). The most effective commercial strategies combine transparency and education: consumers understand trade-offs between immediate visible effects and investments in long-term resilience.

Competitive landscape Many brands already use peptides and plant-derived actives. MPC™ and Phytosan™ NewAge will compete on data quality, supply chain transparency, formulation guidance, and support for marketing claims. CLR’s refreshed human data serves as a differentiator, but long-term adoption will depend on formulators’ ability to translate those data points into compelling, stable products.

Real-world precedents and comparable actives

Understanding how MPC™ and Phytosan™ NewAge fit into the market benefits from looking at precedents.

Peptides as scaffolding boosters Peptide complexes such as palmitoyl pentapeptide (Matrixyl) have been marketed for collagen stimulation and visible wrinkle reduction. Their commercial success demonstrates consumer acceptance of peptides as credible anti-ageing ingredients when supported by data and visible results.

Soy and plant-derived DNA-protective ingredients Soy-derived molecules have appeared in topical and oral products for years. Genistein, for example, has been investigated for antioxidant and anti-inflammatory effects. Brands that position soy fractions around DNA protection and stem cell support must balance claims with robust data to avoid conflating traditional botanical benefits with genomic repair.

What differentiates MPC™ and Phytosan™ NewAge The key distinction is the pairing of rapid structural gains with longer-term genomic and stem-cell benefits, both supported by updated in vivo evidence. That combination provides a clear narrative for product development teams seeking to deliver both quick gratification and measurable long-term improvements.

Practical questions formulators and brands should ask suppliers

When evaluating MPC™ and Phytosan™ NewAge for development, formulators should request specifics that enable rigorous product design.

Ask for:

• Complete study reports: protocols, participant demographics, measurement tools, statistical analyses.
• Recommended concentration ranges and delivery systems validated by the supplier.
• Stability data in representative formula types (serum, cream, oil-in-water emulsion).
• Compatibility matrices with commonly used cosmetics ingredients (retinoids, vitamin C, acids).
• Safety and toxicology dossiers, including irritancy and sensitization results.
• Certificates of analysis and sourcing details (organic certification, non-GMO documentation).
• Suggested claims and language backed by the studies that comply with major regulatory frameworks.

These data points reduce development risk and facilitate accurate marketing claims that withstand scrutiny.

How consumers should evaluate “longevity” products

Consumers face a proliferation of claims. Practical criteria help separate meaningful interventions from marketing noise.

Evaluate the evidence

• Look for human clinical data that specifies endpoints and timeframes.
• Prefer products that explain mechanisms plainly: structural, cellular, or protective.
• Verify that supporting studies are published or available upon request.

Assess product design

• Packaging that limits exposure to air and light preserves actives.
• Ingredient lists where active concentrations are disclosed or where the company provides formulation guidance and recommended usage.
• Regimen instructions that include photoprotection and complementary actives.

Realistic expectations

• Immediate tightening or plumping can coexist with longer-term improvements; both are valid outcomes.
• Longevity-focused products require commitment. Cellular and genomic benefits accrue over weeks to months.

Case study scenarios: integrating MPC™ and Phytosan™ NewAge into product lines

The following scenarios illustrate how brands might deploy these actives across portfolios.

Scenario 1: Premium daily system

• AM: Lightweight serum containing MPC™ for immediate firmness + broad-spectrum SPF.
• PM: Repair cream with Phytosan™ NewAge and humectants to support overnight DNA repair and stem cell maintenance.
• Outcome: Visible improvements within weeks and deeper resilience over several months.

Scenario 2: Targeted booster strategy

• Product: Concentrated ampoule containing both actives for spot treatment.
• Use: Applied to crow’s feet and nasolabial folds nightly for 6–12 weeks.
• Outcome: Rapid visible tightening from MPC™ with cumulative wrinkle smoothing from Phytosan™ NewAge.

Scenario 3: Clinical/professional protocol

• In-clinic microinfusion of a high-percentage MPC™ preparation followed by a take-home Phytosan™ NewAge regimen to sustain cellular repair.
• Outcome: Accelerated remodeling with prolonged maintenance via cellular stabilization.

Each scenario requires tailored stability testing, compatibility checks, and consumer guidance on expected timelines.

Limitations and areas for further research

The available information highlights positive outcomes but raises questions that research should address.

• Long-term durability: How do improvements hold up beyond initial study windows—six months, one year?
• Mechanistic specifics: Which DNA repair pathways and stem cell markers does Phytosan™ NewAge engage? What are the precise DEJ components stimulated by MPC™?
• Population diversity: Do effects vary across ages, skin phototypes, or skin conditions?
• Combination synergies: How do these actives interact with retinoids, peptides of different classes, and procedures like microneedling?

Suppliers and independent researchers can strengthen claims and broaden market acceptance by publishing extended and peer-reviewed studies addressing these topics.

Where this fits into the broader science-based skincare movement

The relaunch of MPC™ and Phytosan™ NewAge highlights a maturing market where mechanistic clarity and human data guide product development. The combination of rapid structural improvement and genomic stabilization is a template for future active portfolios: provide early perceptible benefits while modifying fundamental ageing processes.

This dual strategy mirrors approaches in other health fields—symptom management paired with disease-modifying therapy—and reflects consumer readiness to invest in multi-stage regimens that yield sustained returns. Brands that translate mechanistic evidence into transparent claims and well-designed products are positioned to win trust and long-term loyalty.

Contact and sourcing considerations

Brands interested in adopting MPC™ and Phytosan™ NewAge should engage directly with CLR for technical dossiers, stability guidance, and sample material. Suppliers typically support formulators with recommended usage concentrations, compatibility studies, and claim language aligned with regulatory requirements.

When evaluating suppliers, prioritize those that provide:

• Full clinical study reports and raw data access upon request.
• Technical support for formulation and scale-up.
• Clear documentation for sourcing claims, such as organic and non-GMO certifications.

Closing perspective

Advances in cosmetic science increasingly demand both immediate efficacy and durable, biology-centered outcomes. CLR’s updated in vivo data for MPC™ and Phytosan™ NewAge present a compelling case for pairing structural rebuilding with cellular stabilization. For formulators and brands, the opportunity lies in translating that complementary science into formulations that deliver visible benefits upfront and measurable resilience over time.

FAQ

Q: What differentiates MPC™ from other peptide actives on the market? A: MPC™ is a milk-derived peptide complex formulated to act on both the dermis and the dermal–epidermal junction. Its updated in vivo data show visible firmness and wrinkle reduction within 14 days and superior results compared with placebo. The distinguishing factors are its dual-site action (dermal and DEJ) and the reported rapidity of visible improvement.

Q: How does Phytosan™ NewAge support skin longevity? A: Phytosan™ NewAge targets genomic instability by supporting epidermal stem cell vitality and strengthening natural DNA repair mechanisms. The ingredient is derived from organic, non-GMO soybeans. In vivo results reported by the supplier show significant wrinkle reduction and improvements in firmness and elasticity after 42 days, indicating cumulative cellular benefits.

Q: Can these two actives be used together in one product? A: Yes. Their mechanisms are complementary: MPC™ delivers faster structural improvements while Phytosan™ NewAge builds resilience at a cellular level over weeks. Brands often pair such actives in multi-ingredient formulations or in sequential AM/PM regimens. Compatibility and stability testing are essential when combining actives.

Q: What kinds of products are best suited to each active? A: MPC™ is well-suited to serums and lightweight treatments formulated for rapid penetration and visible tightening. Phytosan™ NewAge fits into repair creams, nightly treatments, and concentrated boosters that emphasize cumulative improvements. Both can appear in targeted ampoules or layered regimen strategies.

Q: How credible are the clinical claims for each ingredient? A: CLR reports human in vivo data for both actives: MPC™ shows visible firmness and wrinkle reduction in 14 days (significantly better than placebo); Phytosan™ NewAge shows significant wrinkle reduction and improved firmness and elasticity after 42 days. Buyers should request full study reports for details on sample size, design, endpoints, and measurement methods to assess claim strength.

Q: What safety and regulatory issues should brands consider? A: Brands must ensure ingredient safety through toxicology and irritation testing and align marketing claims with cosmetic regulations in their markets. For milk-derived and plant-derived materials, verify allergen profiles and source certifications. Maintain accurate INCI labeling and substantiate claims with supplier-provided clinical documentation.

Q: How should formulators protect the actives during product development? A: Use packaging that limits oxygen and light exposure (airless pumps, opaque containers), incorporate stabilizing excipients, conduct accelerated and real-time stability tests, and evaluate compatibility with other actives, surfactants, and preservatives. Encapsulation and delivery systems may enhance penetration and protect labile molecules.

Q: What questions should brands ask CLR or other suppliers before sourcing? A: Request full clinical study reports, recommended use concentrations, stability data in representative formulas, safety and toxicology dossiers, certificates of analysis and sourcing documents (organic/non-GMO), and guidance on compliant claim language.

Q: How quickly should consumers expect to see results? A: According to CLR’s reported data, MPC™ delivered visible firmness and wrinkle reduction within 14 days, whereas Phytosan™ NewAge showed significant wrinkle reduction and improved firmness and elasticity after 42 days. Users should follow recommended application protocols and maintain photoprotection to preserve gains.

Q: Are there known interactions between these actives and common cosmeceutical ingredients like retinoids or vitamin C? A: Interactions depend on formulation design. Retinoids can be combined but may increase irritation risk; staged introduction and tolerance testing are prudent. Vitamin C has stability and pH constraints that could affect peptide stability. Suppliers can provide compatibility data and guidance for co-formulation.

Q: Where can I obtain technical documentation and samples? A: Contact CLR Chemisches Laboratorium Dr. Kurt Richter GmbH through their official channels (info@clr-berlin.com or via www.clr-berlin.com) to request samples, technical dossiers, and clinical study reports.

Q: What further research would strengthen the longevity claims for these actives? A: Extended-duration trials (six months or longer), studies across diverse skin types and ages, mechanistic studies identifying specific proteins and DNA repair pathways affected, and combination trials with established actives would all enhance the evidence base and enable more robust claim-making.